Key result
Ticagrelor monotherapy reduces bleeding ~35% vs. dual antiplatelet therapy in diabetic post-PCI patients.
Why the study?
The impact of ticagrelor monotherapy after a brief period of dual antiplatelet therapy among patients with DM undergoing PCI was unknown.
Does ticagrelor monotherapy after 3 months of dual antiplatelet therapy reduce BARC 2, 3, or 5 bleeding without increasing ischemic events compared to continued ticagrelor plus aspirin in high-risk patients with diabetes mellitus undergoing PCI?
RCT (n=2,620)
placebo-controlled
randomized to aspirin or placebo
Does ticagrelor monotherapy after 3 months of dual antiplatelet therapy reduce BARC 2, 3, or 5 bleeding without increasing ischemic events compared to continued ticagrelor plus aspirin in high-risk patients with diabetes mellitus undergoing PCI?
In high-risk patients with diabetes mellitus undergoing PCI, transitioning to ticagrelor monotherapy after 3 months of dual antiplatelet therapy significantly reduces clinically relevant bleeding without increasing ischemic events compared to continuing ticagrelor plus aspirin.
Answers are grounded in this paper and cite their sources.
Ticagrelor monotherapy reduces bleeding without ischemic harm in diabetic PCI patients; confirms consistency with overall TWILIGHT results in this high-risk subgroup.
BACKGROUND P2Y12 inhibitor monotherapy with ticagrelor after a brief period of dual antiplatelet therapy can reduce bleeding without increasing ischemic harm after percutaneous coronary intervention (PCI). The impact of this approach among patients with diabetes mellitus (DM) remains unknown. OBJECTIVES To examine the effect of ticagrelor monotherapy versus ticagrelor plus aspirin among patients with DM undergoing PCI. METHODS This was a pre-specified analysis of the DM cohort in the TWILIGHT trial. After 3 months of ticagrelor plus aspirin, patients were maintained on ticagrelor and randomized to aspirin or placebo for 1 year. The primary endpoint was Bleeding Academic Research Consortium (BARC) 2, 3 or 5 bleeding. The composite ischemic endpoint was all-cause death, myocardial infarction, or stroke. RESULTS Patients with DM comprised 37% (n=2620) of the randomized cohort and were characterized by more frequent comorbidities and a higher prevalence of multivessel disease. The incidence of BARC 2, 3 or 5 bleeding was 4.5% and 6.7% among patients with DM randomized to ticagrelor plus placebo versus ticagrelor plus aspirin (HR 0.65; 95% CI 0.47-0.91; p=0.012). Ticagrelor monotherapy was not associated with an increase in ischemic events compared with ticagrelor plus aspirin (4.6% vs 5.9%; HR 0.77; 95% CI 0.55 to 1.09; p=0.14). In the overall trial population, there was no significant interaction between DM status and treatment group for the primary bleeding or ischemic endpoints. CONCLUSIONS Compared with ticagrelor plus aspirin, the effect of ticagrelor monotherapy in reducing the risk of clinically relevant bleeding without any increase in ischemic events was consistent among patients with or without DM undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Angiolillo et al. (2020) conducted an RCT in High-risk patients with diabetes mellitus undergoing percutaneous coronary intervention (n=2,620). Ticagrelor plus placebo (ticagrelor monotherapy) vs. Ticagrelor plus aspirin was evaluated on Bleeding Academic Research Consortium (BARC) 2, 3 or 5 bleeding (HR 0.65, 95% CI 0.47-0.91, p=0.012). Ticagrelor monotherapy reduced BARC 2, 3 or 5 bleeding vs ticagrelor plus aspirin in diabetic PCI patients.
Synapse has enriched 10 related papers. Consider them for comparative context: